ELESTRIN Drug Patent Profile

Which patents cover Elestrin, and when can generic versions of Elestrin launch?

Elestrin is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in ELESTRIN is estradiol. There are seventy-five drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the estradiol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Elestrin

A generic version of ELESTRIN was approved as estradiol by BARR LABS INC on October 22^nd, 1997.

Summary for ELESTRIN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	4,091
Drug Prices:	Drug price information for ELESTRIN
What excipients (inactive ingredients) are in ELESTRIN?	ELESTRIN excipients list
DailyMed Link:	ELESTRIN at DailyMed

See drug prices for ELESTRIN

See drug sales revenues for ELESTRIN

Recent Clinical Trials for ELESTRIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Missouri-Columbia	N/A

See all ELESTRIN clinical trials

Pharmacology for ELESTRIN

Drug Class	Estrogen
Mechanism of Action	Estrogen Receptor Agonists

US Patents and Regulatory Information for ELESTRIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	ELESTRIN	estradiol	GEL, METERED;TRANSDERMAL	021813-001	Dec 15, 2006		RX	Yes	Yes

Expired US Patents for ELESTRIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	ELESTRIN	estradiol	GEL, METERED;TRANSDERMAL	021813-001	Dec 15, 2006	7,198,801
Viatris	ELESTRIN	estradiol	GEL, METERED;TRANSDERMAL	021813-001	Dec 15, 2006	7,470,433

International Patents for ELESTRIN

See the table below for patents covering ELESTRIN around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	030312	COMPOSICION NOVEDOSA PARA LA ADMINISTRACION TRANSDERMICA Y/O TRANSMUCOSICA DE COMPUESTOS ACTIVOS, QUE ASEGURA ADECUADOS NIVELES TERAPEUTICOS
Austria	355854
Austria	356636
Austria	485837
Austria	534373
Australia	2001282064

Supplementary Protection Certificates for ELESTRIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0136011	C00136011/03	Switzerland		PRODUCT NMAE: ESTRADIOL UND MEDROXYPROGESTERONACETAT; REGISTRATION NO/DATE: IKS 55288 20000417
0136011	2000C/027	Belgium		PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
0136011	99C0003	Belgium		PRODUCT NAME: ESTRADIOL AND NORETHISTERONE; FIRST REGISTRATION NO/DATE: 403 IS 106 F3 19980928; FIRST REGISTRATION: SE 14007 19980306
0584952	99C0004	Belgium		PRODUCT NAME: ESTRADIOL, HEMIHYDRATE, NORETHISTERONE, ACETATE; NAT. REGISTRATION NO/DATE: NL 23753 19981210; FIRST REGISTRATION: SE - 14 007 19980306
0398460	SPC/GB04/032	United Kingdom		PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
0398460	04C0022	France		PRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211

ELESTRIN (estradiol) market dynamics and financial trajectory: exclusivity, generic risk, and revenue outlook

Last updated: July 30, 2026

ELESTRIN is an estradiol transdermal gel product that competes in a crowded menopause hormone therapy market shaped by substitution pressure, payer controls, and patent-driven generic entry. Financial trajectory in the US hinges on (1) remaining formulation/skin delivery IP and (2) the intensity of generic and authorized-bridge competition for estradiol topical gels and sprays.

What is ELESTRIN (estradiol) and where does it compete in the menopause hormone therapy market?

ELESTRIN is a topical estradiol (transdermal) therapy used for treatment of menopausal vasomotor symptoms (VMS) in select labeling, with dosing tied to estradiol delivery and patient-specific response.

Competitive set (drug class and practical substitution):

• Other estradiol transdermal gels (generic and brand, depending on SKU availability by strength and channel)
• Estradiol transdermal sprays
• Estradiol patches (weekly and twice-weekly generics and brands)
• Other systemic estrogen products (selected by payer and formulary)

Market dynamics that drive share and revenue

• Formulary tiering: Topical estradiol products are routinely preferred by plan designs at the molecule and route level, then tightened by strength, days’ supply, and rebate contracting.
• Switching elasticity: Clinicians switch among transdermal estradiol delivery forms with relatively low clinical friction when estradiol exposure is maintained.
• Price compression: As generics of estradiol topical products expand, branded revenues tend to fall quickly due to rebate-driven net price normalization.
• Channel mix: Retail tends to absorb most initial penetration by generics; specialty-like reimbursement behaviors are less pronounced than oncology, but payer controls still dominate net sales.

How do ELESTRIN sales typically evolve across the patent and generic cycle?

Revenue typically follows a three-stage profile for branded topicals in mature estrogen categories.

Stage 1: Pre-generic competitive pressure

• Brand holds premium pricing and strong prescriber familiarity.
• Growth depends on new patient starts, persistence (refills), and channel contracting.

Stage 2: Post-generic entry

• Rapid net price erosion driven by generic substitution and payer step-therapy.
• Brand loses share even if dosing remains clinically consistent because plans prefer lowest-cost equivalent.

Stage 3: Late-cycle stabilization

• Brand persists in smaller pockets where dosing convenience or prior authorization outcomes favor retention.
• Revenue becomes increasingly sensitive to remaining exclusivity (formulation, method-of-use, or packaging) and to whether a “next wave” of generics appears.

When does ELESTRIN lose exclusivity, and what does that imply for revenue risk?

The dominant financial question is timing of exclusivity loss and the start of full commercial generic availability. Without a verified Orange Book and patent list for ELESTRIN’s specific NDC(s), the only correct action is to omit an exclusivity timeline.

What patents protect ELESTRIN, and how strong is the remaining patent estate for financial shielding?

A defensible assessment requires the ELESTRIN Orange Book patent portfolio by:

• Active ingredient (estradiol) listings
• Dosage form (gel) and strength-specific NDC coverage
• Patent type (composition, formulation, method-of-use, delivery system)
• Expiration dates and any pediatric exclusivity or patent-term adjustment

Without the underlying patent list and dates, a complete and accurate patent-protection map for ELESTRIN cannot be produced.

What generic entry risks exist for ELESTRIN (Paragraph IV, 505(b)(2), or Section viii pathways)?

Generic entry risk for an estradiol topical gel depends on whether challengers can:

• Demonstrate bioequivalence and meet application pathway requirements
• Avoid formulation or method-of-use patent claims
• License or design around skin delivery or excipient systems

A correct risk matrix requires the current ANDA landscape (filings, certifications, and any litigation/settlements) tied to ELESTRIN’s exact Orange Book listings.

What is the Orange Book status of ELESTRIN, and which patents are listed for its gel strengths?

Orange Book status requires the authoritative listing for each ELESTRIN strength and NDC, including:

• Drug substance and drug product registrations
• Patent numbers and expiration dates
• Patent-protection scope strings (where available)
• Exclusivity periods (if any)

Without the ELESTRIN Orange Book listing set, an accuracy-safe status summary cannot be delivered.

How does ELESTRIN compare with competing estradiol topical gels and sprays on pricing power and net sales exposure?

Typical pricing and net sales drivers across competing estradiol topicals:

• Generic density: the more entrenched generic options, the faster branded net prices compress.
• Formulation differentiation: if a brand has a clinically meaningful delivery advantage that prescribers actively prefer, it can slow share loss.
• Contracting: rebate structures can hold relative pricing for a period even after generic entry, but the advantage narrows as plan administrators switch to lowest net cost.
• Payer controls: step edits and prior authorizations favor drugs with the lowest effective cost and easiest authorization.

Implication for ELESTRIN:

• If ELESTRIN’s market position is primarily as a priced alternative within the topical gel class, its net sales trend is likely to track generic penetration and formulary tier movement.

What patent litigation affects ELESTRIN, and how do settlements change entry timing?

Patent litigation materially affects revenue trajectories via injunction leverage, delayed approvals, and settlement-driven “date caps” on entry.

A complete litigation impact assessment requires:

• Case captions and court dates
• Asserted patents and infringement theories
• Parties (brand holder, ANDA filer, challengers)
• Settlement agreements that specify launch dates or design-around commitments

Without a confirmed litigation docket for ELESTRIN’s listed patents, a complete report cannot be created.

What FDA regulatory milestones matter for ELESTRIN’s commercial trajectory?

Key milestones that shape market dynamics:

• NDA/ANDA approval histories for current and competing products
• Labeling changes affecting VMS or other indications
• Pediatric exclusivity triggers (if applicable)
• Label expansions or risk communications that change prescriber behavior

A correct milestone chronology requires the official FDA approval record and current labeling status for ELESTRIN, tied to product-specific NDC(s).

What are the commercial trajectory indicators investors use for estradiol topicals like ELESTRIN?

For branded menopause hormone therapies and their topical competitors, investors usually monitor:

• US prescription trend and TRx share by strength and channel
• Net price after rebates and average manufacturer price (AMP) movements
• Switch rate to lower-cost generics and retention rate among initiating prescribers
• Pharmacy benefit manager formulary changes and prior authorization edits
• Any launch waves tied to ANDA approvals and labeling carve-outs

ELESTRIN-specific figures require product-level data extraction from prescription and sales intelligence databases.

How many competitors and branded-to-generic switches are likely to hit ELESTRIN next?

Competitor density and the number of switching events depend on:

• How many ANDAs are approved for the same estradiol gel strengths
• Whether generics use comparable excipients and delivery technologies
• Whether payers implement class-wide switching or strength-specific substitution

A defensible estimate requires identification of already-approved competitors for the same NDC(s) and the scope of any certified design-around.

Key Takeaways

• ELESTRIN’s financial trajectory in the US is driven by payer-directed substitution within systemic estrogen topicals and by timing of remaining formulation/delivery IP.
• Accurate exclusivity, patent strength, generic entry risk, litigation impact, and revenue outlook require ELESTRIN’s NDC-specific Orange Book listing and the related ANDA/litigation record.
• In mature estradiol topical categories, revenue typically declines after generic density rises and stabilizes at a smaller base share, with net price compression as the primary earnings headwind.

FAQs

1. Which estradiol topical gel strengths drive the biggest share for ELESTRIN prescriptions in the US?
2. How do step edits and prior authorization criteria affect ELESTRIN formulary access versus estradiol patches?
3. What does a typical net price waterfall look like for branded estradiol topical products after generic entry?
4. Which FDA pathways (ANDA vs 505(b)(2)) are used for estradiol topical gel challengers, and how does that change approval timing?
5. What claim types (composition, formulation, method-of-use) most often determine whether an ELESTRIN generic can launch?

References

1. [No citable sources were provided in the prompt, and no product-specific Orange Book, FDA, or litigation records were supplied to support an accurate ELESTRIN market and financial trajectory analysis.]